New 12-week hormone therapy tested for rare tumors and acromegaly
NCT ID NCT05364944
First seen Nov 17, 2025 · Last updated May 25, 2026 · Updated 31 times
Summary
This early-phase study tested a new formulation of octreotide that lasts 12 weeks in people with acromegaly or certain neuroendocrine tumors. The goal was to measure how the drug moves through the body and check its safety. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACROMEGALY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
AP-HM - Hôpital de la Conception, Service d'Endocrinologie et Centre de Référence des Maladies Rares de l'hypophyse
Marseille, 13385, France
-
AP-HP Hopital Bicetre
Le Kremlin-Bicêtre, 94270, France
-
CHU Angers
Angers, 49933, France
-
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano
Milan, 20122, Italy
-
Hospital Universitario Virgen del Rocio
Seville, 41013, Spain
-
Hospital de la Santa Creu i Sant Pau Barcelon
Barcelona, 08041, Spain
-
Mazowiecki Szpital Brodnowski - Zespol Oddzialow Chorob Wewnetrznych, Endokrynologii i Diabetologii
Warsaw, 03-242, Poland
-
Medicover Praxis fur Neuroendokrinologie
Munich, 81667, Germany
-
Rabin Medical Center, Beilinson Hospital, Clalit Health Services by Rabin Medical Center, Beilinson Hospita
Petah Tikva, 49100, Israel
-
Rigshospitalet, Endokrinologisk afdeling
Copenhagen, 2200, Denmark
-
Royal Free London NHS Foundation Trust
London, NW3 2QG, United Kingdom
-
Sheba Medical Center, Endocrine institute
Ramat Gan, 5265601, Israel
-
University Hospital Coventry, WISDEM Centre, UHCW NHS Trust
Coventry, CV2 2DX, United Kingdom
-
Uniwersyteckie Centrum Kliniczne im. Prof. K. Gibinskiego Slaskiego Uniwersytetu Medycznego w Katowicach
Katowice, 40-514, Poland
Conditions
Explore the condition pages connected to this study.